Boothbay Fund Management’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Boothbay Fund Management’s Portfolio CSCI Stock Details CSCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-241	Closed	-$19K	–	1258
2020 Q2	$19K	Hold	241	–	–	﹤0.01%	934
2020 Q1	$12K	Hold	241	–	–	﹤0.01%	814
2019 Q4	$22K	Sell	241 -372	-61%	-$34.7K	﹤0.01%	820
2019 Q3	$63K	Hold	613	–	–	0.01%	717
2019 Q2	$181K	Buy	613 +154	+34%	+$54.3K	0.02%	633
2019 Q1	$213K	Hold	459	–	–	0.02%	590
2018 Q4	$135K	Buy	+459	New	+$110K	0.02%	525

Other funds holding CSCI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

DWM

Dorchester Wealth Management Montreal, Quebec, Canada $501M AUM 16.39% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RFA

Reilly Financial Advisors La Mesa, California $1.35B AUM 22.65% 1-Year Est. Return

Boothbay Fund Management's CSCI Position: Q3 2020 in Review

Boothbay Fund Management sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q3 2020, closing a stake of 241 shares — an estimated $19K sold.

Boothbay Fund Management first reported a position in CSCI in Q4 2018 and held it in 7 quarters. The position peaked at $213K in Q1 2019. 16 funds tracked by Wall St. Rank hold CSCI as of Q3 2020.

Boothbay Fund Management reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
Boothbay Fund Management sold 241 COSCIENS Biopharma Inc. Common Stock shares in Q3 2020, an estimated $19K.
Boothbay Fund Management first reported a position in COSCIENS Biopharma Inc. Common Stock in Q4 2018 and held it in 7 quarters.
Boothbay Fund Management's COSCIENS Biopharma Inc. Common Stock position peaked at $213K in Q1 2019.
16 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q3 2020.

Based on Boothbay Fund Management's 13F filing for Q3 2020, filed 16 Nov 2020.